Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
eNq9mF1v2jAUhu/5FVHuk5B+UDIFqo21G1KrMVq0aTfIJAcwM3bqDz726+cQutHJUVtT7ypK7LznxOf146Okl5sl8VbABWa048dh0/eAZizHdNbxR/fXQdu/7DbSBVqhg2kXYTOMT3wvI0iIjl+OhhNAVITfb28+gn4fuN9teCmbLCCTT+YpiUn4GYn5LSrKOV66Yjj3liDnLO/4hZK7p14qJNdZdNeM/xQFyiCN9k8ORxfjs8PnaVSKvUBVCeA3iM6MokCtNDPFOVDZQxJmjG9r8j210sZiCIIpnsEAyfmAsxXOITeGmCIiwCrIdJ3fAV8RkGUQo3i0yJbCShwt0GYID31z0u/1aE9uZNAM4ovzVitJ4tMkTlpWofjBUpmroD8iysZx66ydJEkENFrCTFss0BfQcxgJ9J3UhQxysKzXgHGJiKNKYdF7ajZHcTg8POuIHIuCoG24EIXtUiGO9DBwjQR3H1J+wT3XkCJ6zf7Rp4qQ6JVZj/YIcZRxSageU1TWkOR6aLsQPUYlbOoragc/udl7EYN4O9lfjJrBP1ATgjNbzGkQKb3RR8N+PeVcA+IDEjDi7gjxDdOcrcXbk+ew0o6yL3bwNIoWPI/HJ0m7FZ+fW2+sH9pWNSfRleKsgEgzCYtjUNOnU3YsZLRTzVKPPnVq0V2PxDJEoKZLCiwZpL352NQ5c7+7nVUNGEU/Xd3bWuarAr69290apXHe+VNsO0C7oL42aG3ir7d7teud9M+Km2kyl7IQ76JojkQgkF6hcMr/C/0PDmF33byTk77qfCqCOkp9Uh2NL6+Y7a57rg84trfdv7/voY0xJFdwRB0qQDvDaP/q7cn8t7F1lvbgCUnchdk1oUhiRl01QmpiVDzuLNB1pddcw+HLdIpr/qzU+jKNqr863UYalX90uo3fUEX/uA==
MmL6BLNHgV1QGfrJ
Listen
